- Home
- Publications
- Publication Search
- Publication Details
Title
Switching of biologics in psoriasis: Reasons and results
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGY
Volume 44, Issue 9, Pages 1015-1019
Publisher
Wiley
Online
2017-05-10
DOI
10.1111/1346-8138.13860
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
- (2015) Richard B. Warren et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
- (2014) Christopher Ritchlin et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: A multicenter, open-label trial (TANGO)
- (2014) Fabio Ayala et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study
- (2013) Karen Minde Fagerli et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry
- (2013) Bente Glintborg et al. ARTHRITIS AND RHEUMATISM
- Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study
- (2013) Vito Di Lernia et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Drug survival rates in patients with psoriasis after treatment with biologics
- (2013) Yoshinori Umezawa et al. JOURNAL OF DERMATOLOGY
- Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis
- (2011) Vito Di Lernia et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
- (2011) Atsuyuki IGARASHI et al. JOURNAL OF DERMATOLOGY
- Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
- (2011) Bruce E. Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study
- (2011) Alice B. Gottlieb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE
- (2011) J.-P. Ortonne et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept
- (2010) P.P.M. Van Lümig et al. BRITISH JOURNAL OF DERMATOLOGY
- Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial
- (2010) Hideshi Torii et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
- (2010) Akihiko ASAHINA et al. JOURNAL OF DERMATOLOGY
- Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis
- (2010) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments
- (2009) Annamaria Mazzotta et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started